Parkinson's Disease Drugs Market Globally Expected to Drive Growth till 2020
There are approximately 2 million people living with Parkinson’s in the United States and around 12 million people worldwide. Close to 70,000 Americans are diagnosed with Parkinson’s every year. United States expenditure on Parkinson’s each year is close to US$ 14.0 billion. In UK around 1.5 million people are suffering from Parkinson’s. Number of cases of Parkinson’s will increase about 30-35% by 2020 worldwide. Genetically Caucasians people have a higher prevalence than people of Asian and African descent. PD cases are more in the Midwest and Northeast regions of the US than Western and Southern regions.
As of now there is no single treatment available for PD as the disease symptoms differ from person to person based on their age, severity of disease and level of physical activity. Complete treatment regimen of PD includes medications, education, support, exercise, physical and speech therapy, and nutrition. The major aim of medication in PD is to increase the level of dopamine in the brain and to inhibit the action of other substances that affects dopamine such as acetylcholine.
Click For Full Report And Request TOC@ http://www.sa-brc.com/Global-Parkinsons-Disease-Drugs-Market-Assessment--Forecast-2016---2020/upcomingdetail32
Levodopa (L-dopa) is one of the most commonly used drug molecule for controlling the symptoms of Parkinson's disease, particularly rigidity and tremors. In recent years, drug manufacturers have tried to develop a formulation of carbidopa/levodopa that would release more slowly over time, and keep levodopa levels more even, thus reducing “off times” for people with Parkinson’s disease. In 2015, the U.S. FDA approved extended release carbidopa/levodopa combinations RYTARY by Impax Pharmaceuticals and Duopa by AbbVie. Duopa is a combination of carbidopa and levodopa and is the first to be effective for 16 hours, compared to oral formulations that last up to four hours following a single dose. Other popular carbidopa/levodopa combination for treatment currently in use is Sinemet. Emerging MAO-B inhibitor Safinamide (Newron Pharmaceuticals/Zambon Pharma) has won the EU approval in January 2015 and is also known to reduce dyskinesia or involuntary movements that are sometimes induced by Levodopa. Leading dopamine agonists, GSK’s/Skye Pharma’s Requip/XL/LKP/RP and Boehringer Ingelheim’s riapex/ Mirapexin/Sifrol also contribute significantly sales among therapies used to treat PD.
Some of the available PD drugs that will lose patent protection by 2020 are Teva/Lundbeck’s Azilect/Agilect, Novartis/Orion Pharma’s Comtan/Comtess/Staleva and GlaxoSmithKline’s Requip. Few of the leading pharmaceutical companies in the PD drugs market are GSK, Novartis, Newron Pharmaceuticals, Teva Pharma, Addex and Abbott. This report intends to provide qualitative analysis for market segmentation, treatment algorithms, drivers and inhibitors, opportunities (organic and non-organic), pipeline analysis and the competitive landscape of the market. Along with this quantitative analysis will be provided for treatment by disease segments and geography.
For More Research Reports@ http://www.sa-brc.com/Pharmaceuticals/upcoming2
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.
10685-B Hazelhurst Drive,
Houston, Texas 77043,
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Drugs Market Globally Expected to Drive Growth till 2020 here
News-ID: 400718 • Views: 527
More Releases from SA-BRC
Biochip Market Analysis by Application and Trend 2017-2021
Biochips allow simultaneous testing of higher number of analytes to achieve high throughput and low cost per test. Nanotechnology has helped in miniaturization of devices to achieve higher performance standards. Microarrays are most important part of biochips which send signals to the biochip to deliver end results. Microfluidic biochips have become modern alternative to routine laboratories. Microfluidic technology which enables controlling flow of liquids in micro and pico quantities has
Acute Myeloid Leukemia Therapeutics Market Share, Analysis and Segments 2017-202 …
Acute myeloid leukemia is a cancer of blood cells and involves proliferation of abnormal blood cell types and subsequent replacement of bone marrow with cancerous cells. Major leukemia types include myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia, megakaryocytic. Treatment of leukemia mainly depends on the type of leukemia and stage. Acute myeloid leukemia therapeutics market is rich with branded as well as generic drugs classified under various classes including antineoplastic agents, corticosteroids, tyrosine
Companion Diagnostics Market Share, Trends Analysis: 2017-2021
Companion diagnostics has revolutionized cancer therapeutics and enabled physicians to select specific treatment pattern from of myriad of drugs for cancer treatment. This has improved treatment outcome manyfold and has now become and indispensable part of personalized medicine. The companion diagnostics market received great attention post success of Herceptin (trastuzumab) and Gleevec (imatinib). Rapid adoption of companion diagnostics and supportive regulatory agencies have encouraged researchers to seek molecules that target
North America and Europe Bionic Eye Market Segment Analysis And Forecast: 2017-2 …
Sudden surge in bionic eye market was experienced recently after the National Health Service (NHS) announced the sponsorship to implant bionic eyes in ten patients. The bionic eye can help regain vision in individuals with visual impairment. Although currently two bionic eye systems has received regulatory approvals, other companies in the bionic eye market are also trying to develop new technology that can help in regaining visual sense in patients. The
More Releases for Parkinson
QualitySolicitors Parkinson Wright invest in the future
QualitySolicitors Parkinson Wright has selected Liberate from Linetime as its business-wide legal services software platform. The Worcestershire based practice, with over 100 staff, operate from 4 offices and have a highly regarded reputation for their services including residential property, private client, family, dispute resolution and commercial. The firm also has its own estate agency. The firm recognised that to continue delivering high quality services to its clients it needed to provide
Slitter Market Analysis Report By Key Players- Kampf, Euromac, Parkinson Technol …
UpMarketResearch offers a latest published report on “Global Slitter Market Industry Analysis and Forecast 2018-2025” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 136 pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Get Free Sample Report@ https://www.upmarketresearch.com/home/requested_sample/2980 The report begins with the overview of the Slitter market and updates
Wolff Parkinson White syndrome Market found Future opportunities of 2023
The Analysis presents the study of Global Wolff Parkinson White syndrome Market facilitating the regional and country wise analysis covering the strategic analysis of each market player and the market share they hold Wolff Parkinson White Syndrome Market Information: By Types (Type A, Type B) By Diagnosis (Electrocardiogram (ECG), Electrophysiological Testing, Others) By Treatment (Drugs (Anti-Arrhythmic, Beta-Blockers, Others), Cardioversion, Radiofrequency Catheter Ablation, Surgery, Artificial Pacemaker, Others) By End Users - Global
PARKINSON RESEARCH FOUNDATION’S (PRF) WESTERN CARIBBEAN FOURTH EDUCATIONAL CRU …
The Parkinson Research Foundation (PRF), a non-profit organization with a dedicated patient education program, will return to the Western Caribbean for its fourth educational cruise. PRF developed its educational cruise program to give Parkinson patients, caregivers family and loved ones unrivaled access to experts in the movement-disorder field. After visiting the Bahamas and Alaska on the first two respective PRF cruises, PRF’s ventured to the Western Caribbean on its most
PARKINSON RESEARCH FOUNDATION (PRF) Develops New Patient Outreach Program
One of the principal missions of the Parkinson Research Foundation (PRF) that distinguishes it from other Parkinson organizations is PRF’s focus on patient education; specifically education that enables Parkinson patients and their caregivers to live fuller and more comfortable lives with Parkinson's disease. The Foundation’s educational events, including educational cruises, gather leading Parkinson experts, therapists and nutritionists from across the country to offer life-changing tools and knowledge for individuals affected
Parkinson`s Disease:New Hope Educational Conference
PARKINSON’S DISEASE: NEW HOPE EDUCATIONAL CONFERENCE Become knowledgeable about the advancements in surgery The Parkinson Research Foundation is proud to announce that Dr. James Schumacher will be speaking about advances in surgery at our fourth annual New Hope for Parkinson’s conference on November 1st in Boca Raton. Dr. Schumacher is an internationally known expert in the field of neurosurgical treatment of Parkinson’s disease and movement disorders. He has an extensive background and